Diagnostic testing for galactose-alpha-1,3-galactose, United States, 2010 to 2018

BackgroundAlpha-gal syndrome (AGS) is an emerging immunoglobulin E (IgE)–mediated allergy to galactose-alpha-1,3-galactose (alpha-gal). The geographic distribution and burden of AGS in the United States are unknown.ObjectiveTo characterize alpha-gal IgE testing patterns describe trends from 2010 2018 States.MethodsThis retrospective analysis included all persons tested for antibodies by Viracor-IBT Laboratories (Lee’s Summit, Missouri), primary site States. Data age sex person tested, specimen state origin, collection date, result value; with at least 1 positive test (?0.1 kU/L) were compared negatives. Proportions results calculated using US Census population estimates.ResultsOverall, 122,068 specimens 105,674 during July 1, 2010, December 31, 2018. Nearly one-third (34,256, 32.4%) had result. number receiving increased 6-fold 1110 2011 7798 Of those results, mean [SD] was 46.9 (19.8) years; men more likely than women (43.3% vs 26.0%). Arkansas, Virginia, Kentucky, Oklahoma, Missouri highest who a per 100,000 population.ConclusionMore 34,000 persons, most presumably symptomatic, have received alpha-gal, suggesting increasingly recognized public health problem. consistent exposure Amblyomma americanum ticks.